Immunotherapy drug avelumab aims to prevent cancer return in rare urinary tract cancer
NCT ID NCT07225374
First seen Nov 06, 2025 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This phase II trial tests whether the immunotherapy drug avelumab can keep upper tract urothelial carcinoma from coming back after standard cisplatin-based chemotherapy. About 48 adults with high-risk muscle-invasive or node-positive disease who have completed chemotherapy without recurrence will receive avelumab infusions every two weeks for up to a year. The main goal is to see how long participants remain cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Gangnam, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avelumab (immunotherapy drug)
What this could lead to
If successful, this could show that maintenance avelumab helps keep cancer from returning after chemotherapy in upper tract urothelial carcinoma.
What could go wrong
This is a small, early-phase study (48 people) with no control group, so results may not be definitive. Avelumab can cause immune-related side effects like inflammation of organs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.